

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 11, 2020
PDL Changes Effective Date: October 1, 2020



The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2020, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ACNE AGENTS	isotretinoin
ANTICONVULSANTS	NAYZILAM (midazolam)
ANTICONVULSANTS	VALTOCO (diazepam)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	NURTEC ODT (rimegepant)
ANTIMIGRAINE AGENTS, TRIPTANS & RELATED AGENTS	naratriptan
ANTIMIGRAINE AGENTS, TRIPTANS & RELATED AGENTS	zolmitriptan tablets/ODT
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	ROZLYTREK (entrectinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	TURALIO (pexidartinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	XTANDI (enzalutamide)
ANTIPARKINSON'S AGENTS (Oral)	entacapone
HYPOGLYCEMICS, GLUCAGON	BAQSIMI (glucagon) ^{Step Edit}
HYPOGLYCEMICS, GLUCAGON	glucagon vial
HYPOGLYCEMICS, GLUCAGON	glucagon kit
IMMUNE GLOBULINS	XEMBIFY
IMMUNOLOGIC THERAPIES FOR ASTHMA	FASENRA PEN AUTOINJECTOR (benralizumab)
IMMUNOLOGIC THERAPIES FOR ASTHMA	NUCALA AUTOINJECTOR (mepolizumab)
SELECT CONTRACEPTIVES, INTRAVAGINAL	ANNOVERA (segesterone/ethinyl estradiol)
SICKLE CELL AGENTS	DROXIA (hydroxyurea)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 11, 2020
PDL Changes Effective Date: October 1, 2020



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ACNE AGENTS	ABSORICA LD(isotretinoin)
ACNE AGENTS	AKLIEF (trifarotene)
ACNE AGENTS	AMZEEQ FOAM (minocycline)
ACNE AGENTS	ARAZLO LOTION (tazarotene)
ANDROGENIC AGENTS	JATENZO (testosterone undecanoate)
ANTIBIOTICS (MISCELLANEOUS)	XENLETA (lefamulin)
ANTIBIOTICS, TOPICAL	XEPI CREAM (ozenoxacin)
ANTICONVULSANTS	XCOPRI (cenobamate)
ANTIDEPRESSANTS, OTHER	DRIZALMA SPRINKLE (duloxetine)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	UBRELVY (ubrogepant)
ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR	VYEPTI (eptinezumab)
ANTIMIGRAINE AGENTS, TRIPTANS & RELATED AGENTS	REYVOW (lasmiditan)
ANTIMIGRAINE AGENTS, TRIPTANS & RELATED AGENTS	TOSYMRA (sumatriptan)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	AYVAKIT (avapritinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	BRUKINSA (zanubrutinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	INREBIC (fedratinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	KOSELUGO (selumetinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	NUBEQA (darolutamide)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	PEMAZYRE (pemigatinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	RETEVMO (selpercatinib)
ANTINEOPLASTICS – SELECTED SYSTEMIC	TABRECTA (capmatinib)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 11, 2020
PDL Changes Effective Date: October 1, 2020



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ENZYME INHIBITORS	
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	TAZVERIK (tazemetostat)
ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS	TUKYSA (tucatinib)
ANTIPARKINSON’S AGENTS (Oral)	NOURIANZ (istradefylline)
ANTIPSYCHOTICS	CAPLYTA (lumateperone)
ANTIPSYCHOTICS	SECUADO PATCH (asenapine)
BRONCHODILATORS & COPD AGENTS	DUAKLIR PRESSAIR (aclidinium/formoterol)
BRONCHODILATORS, BETA AGONIST	PROAIR DIGIHALER (albuterol)
CALCIUM CHANNEL BLOCKERS	KATERZIA (amlodipine)
COLONY STIMULATING FACTORS	ZIEXTENZO (pegfilgrastim-bmez)
CYSTIC FIBROSIS AGENTS	TRIKAFTA (elixacaftor/ tezacaftor/ivacaftor)
CYTOKINE & CAM ANTAGONISTS	RINVOQ (upadacitinib)
FACTOR DEFICIENCY PRODUCTS	ESPEROCT
H. PYLORI COMBINATION TREATMENTS	TALICIA (omeprazole/amox/rifabutin)
HYPERURICEMIA & GOUT	GLOPERBA (colchicine)
HYPOGLYCEMICS, GLUCAGON	GVOKE (glucagon)
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	RYBELSUS (semaglutide)
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS	TRIJARDY XR (empagliflozin/linagliptan/metformin)
IMMUNE GLOBULINS	ASCENIV
LIPOTROPICS, OTHER	NEXLETOL (bempedoic acid)
LIPOTROPICS, OTHER	NEXLIZET (bempedoic acid/ezetimibe)
MISCELLANEOUS BRAND/GENERIC	PALFORZIA (peanut allergen-dnfp)
MULTIPLE SCLEROSIS AGENTS	VUMERITY (diroximel fumarate)
MUSCULAR DYSTROPHY AGENTS	VYONDYS 53 (golodirsen)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 11, 2020
PDL Changes Effective Date: October 1, 2020



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
NSAIDS	RELAFEN DS (nabumetone)
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS	ZERVIAE (cetirizine)
SEDATIVE HYPNOTICS	DAYVIGO (lemborexant)
SICKLE CELL AGENTS	ADAKVEO (crizanlizumab)
SICKLE CELL AGENTS	HYDREA (hydroxyurea)
SICKLE CELL AGENTS	OXBRYTA (voxelotor)
STEROIDS (Topical)	TOVET Foam (clobetasol)
STIMULANTS AND RELATED AGENTS	WAKIX (pitolisant)
STIMULANTS AND RELATED AGENTS	XYREM (sodium oxybate)

Step Edit- after a trial and failure of a generic product

DRAFT